[1] Narayanan A, Turcan S. The magnifying GLASS:longitudinal analysis of adult diffuse gliomas[J]. Cell, 2020, 180:407-409. [2] Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System:a summary[J]. Neuro Oncol, 2021, 23:1231-1251. [3] Bischof J, Westhoff MA, Wagner JE, Halatsch ME, Trentmann S, Knippschild U, Wirtz CR, Burster T. Cancer stem cells:the potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells[J]. Tumour Biol, 2017, 39:1010428317692227. [4] Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors:function and therapeutic targeting[J]. Mol Cancer Res, 2008, 6:1795-1806. [5] Liu XX, Li JR, Luo ZQ, Lu GM, Zhang ZQ. Progress of erythropoietin-producing hepatocellular A2 receptor in glioma[J]. Zhong Liu Yan Jiu Yu Lin Chuang, 2021, 33:702-705[.刘宵雪, 李建瑞, 骆仲强, 卢光明, 张志强. 促红细胞生成素产生肝细胞受体2 在脑胶质瘤中的研究进展[J]. 肿瘤研究与临床, 2021, 33:702-705.] [6] Li X, Wang Y, Wang Y, Zhen H, Yang H, Fei Z, Zhang J, Liu W, Wang Y, Zhang X. Expression of EphA2 in human astrocytic tumors:correlation with pathologic grade, proliferation and apoptosis[J]. Tumour Biol, 2007, 28:165-172. [7] Suo F, Zhong B, Lu F, Dong Z. The combined use of EphA2/MMP-2 expression and MRI findings contributes to the determination of cerebral glioma grade[J]. Oncol Lett, 2019, 18:5607-5613. [8] Luan J, Wu M, Wang X, Qiao L, Guo G, Zhang C. The diagnostic value of quantitative analysis of ASL, DSC-MRI and DKI in the grading of cerebral gliomas:a meta-analysis[J]. Radiat Oncol, 2020, 15:204. [9] Falk Delgado A, Nilsson M, van Westen D, Falk Delgado A. Glioma grade discrimination with MR diffusion kurtosis imaging:a meta-analysis of diagnostic accuracy[J]. Radiology, 2018, 287:119-127. [10] Qazi MA, Vora P, Venugopal C, Adams J, Singh M, Hu A, Gorelik M, Subapanditha MK, Savage N, Yang J, Chokshi C, London M, Gont A, Bobrowski D, Grinshtein N, Brown KR, Murty NK, Nilvebrant J, Kaplan D, Moffat J, Sidhu S, Singh SK. Cotargeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma[J]. Cancer Res, 2018, 78:5023-5037. [11] Qi XX, Shi DF, Ren SX, Zhang SY, Li L, Li QC, Guan LM. Histogram analysis of diffusion kurtosis imaging derived maps may distinguish between low and high grade gliomas before surgery[J]. Eur Radiol, 2018, 28:1748-1755. [12] Hempel JM, Schittenhelm J, Brendle C, Bender B, Bier G, Skardelly M, Tabatabai G, Castaneda Vega S, Ernemann U, Klose U. Histogram analysis of diffusion kurtosis imaging estimates for in vivo assessment of 2016 WHO glioma grades:a cross-sectional observational study[J]. Eur J Radiol, 2017, 95:202-211. [13] Pogosbekian EL, Pronin IN, Zakharova NE, Batalov AI, Turkin AM, Konakova TA, Maximov II. Feasibility of generalised diffusion kurtosis imaging approach for brain glioma grading[J]. Neuroradiology, 2021, 63:1241-1251. [14] Tan Y, Mu W, Wang XC, Yang GQ, Gillies RJ, Zhang H. Whole-tumor radiomics analysis of DKI and DTI may improve the prediction of genotypes for astrocytomas:a preliminary study[J]. Eur J Radiol, 2020, 124:108785. [15] Kimura Y, Sato N, Ota M, Shigemoto Y, Morimoto E, Enokizono M, Matsuda H, Shin I, Amano K, Ono H, Sato W, Yamamura T. Brain abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome:evaluation by diffusional kurtosis imaging and neurite orientation dispersion and density imaging[J]. J Magn Reson Imaging, 2019, 49:818-824. [16] Van Cauter S, De Keyzer F, Sima DM, Sava AC, D'Arco F, Veraart J, Peeters RR, Leemans A, Van Gool S, Wilms G, Demaerel P, Van Huffel S, Sunaert S, Himmelreich U. Integrating diffusion kurtosis imaging, dynamic susceptibility-weighted contrast-enhanced MRI, and short echo time chemical shift imaging for grading gliomas[J]. Neuro Oncol, 2014, 16:1010-1021. [17] Zhao J, Wang YL, Li XB, Hu MS, Li ZH, Song YK, Wang JY, Tian YS, Liu DW, Yan X, Jiang L, Yang ZY, Chu JP. Comparative analysis of the diffusion kurtosis imaging and diffusion tensor imaging in grading gliomas, predicting tumour cell proliferation and IDH-1 gene mutation status[J]. J Neurooncol, 2019, 141:195-203. [18] Hectors SJ, Semaan S, Song C, Lewis S, Haines GK, Tewari A, Rastinehad AR, Taouli B. Advanced diffusion -weighted imaging modeling for prostate cancer characterization:correlation with quantitative histopathologic tumor tissue composition:a hypothesis-generating study[J]. Radiology, 2018, 286:918-928. [19] Beppu T, Inoue T, Shibata Y, Yamada N, Kurose A, Ogasawara K, Ogawa A, Kabasawa H. Fractional anisotropy value by diffusion tensor magnetic resonance imaging as a predictor of cell density and proliferation activity of glioblastomas[J]. Surg Neurol, 2005, 63:56-61. [20] Yang X, Knopp MV. Quantifying tumor vascular heterogeneity with dynamic contrast-enhanced magnetic resonance imaging:a review[J]. J Biomed Biotechnol, 2011:ID732848. [21] Hansen B, Shemesh N, Jespersen SN. Fast imaging of mean, axial and radial diffusion kurtosis[J]. Neuroimage, 2016, 142:381-393. [22] Glenn GR, Helpern JA, Tabesh A, Jensen JH. Quantitative assessment of diffusional kurtosis anisotropy[J]. NMR Biomed, 2015, 28:448-459. [23] Van Cauter S, Veraart J, Sijbers J, Peeters RR, Himmelreich U, De Keyzer F, Van Gool SW, Van Calenbergh F, De Vleeschouwer S, Van Hecke W, Sunaert S. Gliomas:diffusion kurtosis MR imaging in grading[J]. Radiology, 2012, 263:492-501. [24] Hu LS, Hawkins-Daarud A, Wang L, Li J, Swanson KR. Imaging of intratumoral heterogeneity in high-grade glioma[J]. Cancer Lett, 2020, 477:97-106. [25] Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme[J]. Mol Cancer Res, 2005, 3:541-551. [26] Wu Q, Xu L, Wang C, Fan W, Yan H, Li Q. MicroRNA-124-3p represses cell growth and cell motility by targeting EphA2 in glioma[J]. Biochem Biophys Res Commun, 2018, 503:2436-2442. [27] Bielamowicz K, Fousek K, Byrd TT, Samaha H, Mukherjee M, Aware N, Wu MF, Orange JS, Sumazin P, Man TK, Joseph SK, Hegde M, Ahmed N. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma[J]. Neuro Oncol, 2018, 20:506-518. [28] Day BW, Stringer BW, Wilson J, Jeffree RL, Jamieson PR, Ensbey KS, Bruce ZC, Inglis P, Allan S, Winter C, Tollesson G, Campbell S, Lucas P, Findlay W, Kadrian D, Johnson D, Robertson T, Johns TG, Bartlett PF, Osborne GW, Boyd AW. Glioma surgical aspirate:a viable source of tumor tissue for experimental research[J]. Cancers (Basel), 2013, 5:357-371. [29] Zhang SS, Yu L. Research progress of MRI in glioma grading and molecular genetic biomarkers[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2017, 17:69-73[.张姗姗, 于林. 胶质瘤分级及分子遗传学标志物相关磁共振成像研究进展[J]. 中国现代神经疾病杂志, 2017, 17:69-73.] [30] Xu Z, Ke C, Liu J, Xu S, Han L, Yang Y, Qian L, Liu X, Zheng H, Lv X, Wu Y. Diagnostic performance between MR amide proton transfer (APT) and diffusion kurtosis imaging (DKI) in glioma grading and IDH mutation status prediction at 3 T[J]. Eur J Radiol, 2021, 134:109466. |